异基因干细胞移植后嵌合抗原受体T细胞疗法治疗复发/难治性大B细胞淋巴瘤 - Suppr

Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.

作者信息

Lutfi Forat, Holtzman Noa, Siglin Jonathan, Bukhari Ali, Mustafa Ali Moaath, Kim Dong, Sanchez-Petitto Gabriela, Gottlieb David, Ruehle Kathleen, Hutnick Elizabeth, Gahres Natalie, Hankey Kim, Lee Seung, Kocoglu Mehmet, Yared Jean, Hardy Nancy, Rapoport Aaron, Dahiya Saurabh

机构信息

Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA.

Medicine, University of Maryland Medical Center, Baltimore, MD, USA.

出版信息

Br J Haematol. 2021 Jan;192(1):212-216. doi: 10.1111/bjh.17121. Epub 2020 Nov 10.

DOI:10.1111/bjh.17121

PMID:33169845

Abstract

摘要

相似文献

Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.

Br J Haematol. 2021 Jan;192(1):212-216. doi: 10.1111/bjh.17121. Epub 2020 Nov 10.

Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Curr Hematol Malig Rep. 2021 Feb;16(1):72-81. doi: 10.1007/s11899-021-00610-y. Epub 2021 Feb 22.

Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.

Hematol Oncol Clin North Am. 2020 Aug;34(4):701-714. doi: 10.1016/j.hoc.2020.02.006. Epub 2020 Apr 16.

Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort.

Cytotherapy. 2024 Oct;26(10):1163-1169. doi: 10.1016/j.jcyt.2024.05.002. Epub 2024 May 5.

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.

Leukemia. 2019 Oct;33(10):2540-2544. doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21.

Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.

Immunotherapy. 2019 Jan;11(1):37-44. doi: 10.2217/imt-2018-0089.

Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.

Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10.

Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation.

Br J Haematol. 2021 Dec;195(5):805-811. doi: 10.1111/bjh.17737. Epub 2021 Jul 28.

Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?

J Clin Oncol. 2021 Feb 10;39(5):487-498. doi: 10.1200/JCO.20.01447. Epub 2021 Jan 12.

Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.

Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.

引用本文的文献

Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.

Ann Hematol. 2025 Jan;104(1):841-845. doi: 10.1007/s00277-024-06150-8. Epub 2024 Dec 30.

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.

Leukemia. 2025 Feb;39(2):431-437. doi: 10.1038/s41375-024-02467-5. Epub 2024 Nov 19.

Sclerotic chronic cutaneous graft-versus-host-disease following pseudoallogeneic chimeric antigen receptor T-cell therapy.

JAAD Case Rep. 2024 Jul 6;52:42-45. doi: 10.1016/j.jdcr.2024.06.014. eCollection 2024 Oct.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Cell Oncol (Dordr). 2025 Feb;48(1):219-237. doi: 10.1007/s13402-024-00984-0. Epub 2024 Aug 27.

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.

J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829.

Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan.

Cancer Med. 2023 Dec;12(24):21761-21769. doi: 10.1002/cam4.6741. Epub 2023 Nov 28.

Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant. 2023 Oct;58(10):1075-1083. doi: 10.1038/s41409-023-02073-6. Epub 2023 Jul 29.

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.

Front Immunol. 2022 Aug 8;13:960412. doi: 10.3389/fimmu.2022.960412. eCollection 2022.

Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Int J Hematol. 2022 Sep;116(3):315-329. doi: 10.1007/s12185-022-03398-6. Epub 2022 Jun 23.

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.

Front Immunol. 2022 May 18;13:887866. doi: 10.3389/fimmu.2022.887866. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献